DE69737870D1 - Medikamente für die diagnostik von autoimmunerkrankungen - Google Patents

Medikamente für die diagnostik von autoimmunerkrankungen

Info

Publication number
DE69737870D1
DE69737870D1 DE69737870T DE69737870T DE69737870D1 DE 69737870 D1 DE69737870 D1 DE 69737870D1 DE 69737870 T DE69737870 T DE 69737870T DE 69737870 T DE69737870 T DE 69737870T DE 69737870 D1 DE69737870 D1 DE 69737870D1
Authority
DE
Germany
Prior art keywords
medicaments
diagnosis
autoimmune diseases
autoimmune
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69737870T
Other languages
English (en)
Other versions
DE69737870T2 (de
Inventor
Shoichi Ozaki
Junko Sobajima
Hiroko Uesugi
Takahiro Okazaki
Masao Tanaka
Kazuwa Nakao
Michiteru Yoshida
Hitoshi Shirakawa
Fumio Osakada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaneka Corp
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP26643196A external-priority patent/JP3472048B2/ja
Application filed by Kaneka Corp filed Critical Kaneka Corp
Publication of DE69737870D1 publication Critical patent/DE69737870D1/de
Application granted granted Critical
Publication of DE69737870T2 publication Critical patent/DE69737870T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
DE69737870T 1996-07-17 1997-05-15 Medikamente für die diagnostik von autoimmunerkrankungen Expired - Lifetime DE69737870T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP18794596 1996-07-17
JP18794596 1996-07-17
JP26643196 1996-10-07
JP26643196A JP3472048B2 (ja) 1995-10-09 1996-10-07 自己免疫疾患の診断薬
PCT/JP1997/001647 WO1998002744A1 (fr) 1996-07-17 1997-05-15 Medicaments pour le diagnostic de maladies auto-immunes

Publications (2)

Publication Number Publication Date
DE69737870D1 true DE69737870D1 (de) 2007-08-09
DE69737870T2 DE69737870T2 (de) 2008-02-07

Family

ID=26504659

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69737870T Expired - Lifetime DE69737870T2 (de) 1996-07-17 1997-05-15 Medikamente für die diagnostik von autoimmunerkrankungen

Country Status (6)

Country Link
US (2) US6822078B2 (de)
EP (2) EP0964250B1 (de)
AU (1) AU719555B2 (de)
CA (1) CA2262443A1 (de)
DE (1) DE69737870T2 (de)
WO (1) WO1998002744A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
BR0209689A (pt) * 2001-05-15 2006-02-07 Long Island Jewish Res Inst Uso de fragmento de hmg como agente anti-inflamatório
US20040141948A1 (en) * 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
CA2505682A1 (en) * 2002-11-20 2004-06-03 Kevin J. Tracey Use of hmgb polypeptides for increasing immune responses
US20040156851A1 (en) * 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CN1878793A (zh) 2003-09-11 2006-12-13 鉴定医疗有限公司 拮抗hmgb1的单克隆抗体
WO2006012373A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
CN101132811B (zh) 2004-10-22 2012-05-30 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
EP1909834A2 (de) * 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Verwendung von hmgb1-antagonisten zur behandlung von entzündungskrankheiten
WO2007076200A2 (en) * 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
GB0618496D0 (en) * 2006-09-20 2006-11-01 Common Services Agency Blood typing
EP2123298A4 (de) * 2007-02-15 2011-09-28 Univ Fukuoka Mittel zur unterdrückung der abstossung bei organtransplantationen mit anti-hmgb-1-antikörper
WO2008099913A1 (ja) 2007-02-15 2008-08-21 Kumamoto University ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
US20100216977A1 (en) * 2007-02-15 2010-08-26 Kyushu University, National University Corporation Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody
FR2936060B1 (fr) * 2008-09-17 2010-11-19 Assist Publ Hopitaux De Paris Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire.
ES2413437T3 (es) * 2010-03-10 2013-07-16 Institut Pasteur HMGB1 y anticuerpos anti-HMGB1 en pacientes infectados por VIH especialmente con trastornos neurológicos
IT1406051B1 (it) * 2010-08-05 2014-02-06 D M G Italia S R L Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
WO2013103628A1 (en) * 2012-01-03 2013-07-11 The University Of North Carolina At Chapel Hill Peptides and methods for detecting mpo-anca
RU2497122C1 (ru) * 2012-07-23 2013-10-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханский государственный университет" Способ прогнозирования развития избыточного бактериального роста в кишечнике у пациентов после холецистэктомии

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay

Also Published As

Publication number Publication date
AU719555B2 (en) 2000-05-11
CA2262443A1 (en) 1998-01-22
US6822078B2 (en) 2004-11-23
AU2789397A (en) 1998-02-09
WO1998002744A1 (fr) 1998-01-22
EP0964250B1 (de) 2007-06-27
EP1577671A1 (de) 2005-09-21
DE69737870T2 (de) 2008-02-07
US20020009749A1 (en) 2002-01-24
EP0964250A4 (de) 2002-09-18
EP0964250A1 (de) 1999-12-15
US20040229279A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
DE69737870D1 (de) Medikamente für die diagnostik von autoimmunerkrankungen
DE59007313D1 (de) Verbindungselement für die Osteosynthese.
DE29580137U1 (de) Zweiteilige Vorrichtung für die Verabreichung von Arzneimitteln
DE29580420U1 (de) Sensor für die nichtinvasive Blutanalyse
ATE238773T1 (de) Arzneimittel für die kombination piperidinoalkanol-dekongestivum
DE69401099T2 (de) Mikrorillen für die Entwurf von breitbandiger klinischer Ultraschallwandler
DE69018379T2 (de) System für die Atherektomie.
DE19500856C2 (de) Ultraschall-Diagnosesystem
DE69629869D1 (de) Messeinrichtung für die Aktivität von Tieren
DE9409231U1 (de) Beatmungsgerät für die Schlafmedizin
DE69331228T4 (de) Heilmittel für thrombozytopenia
DE69333167D1 (de) Diagnostischer test spezifisch für die latente matrix metalloproteinase no. 9
DE69830654D1 (de) Heilmittel für die drogenabhängigkeit
DE69811931D1 (de) Mri-mittel für die verabreichung von therapeutischen mitteln
FR2653118B1 (fr) Hydrogenation du citral.
DE69005392D1 (de) Auftragskopf für die Auflegung von Verbundwerkstoffbänder.
DE69736406D1 (de) Feste arzneizubereitung für die mundhygiene
FI900451A0 (fi) Kliniska tillaempningar.
DE3854386D1 (de) Messsystem für die Bruchsteifheit.
DE69502167D1 (de) Geträgerte Katalysatorsysteme für die Herstellung von Ethylen-Propylen-Copolymeren
DE69007374D1 (de) Injektionssystem für die Behandlung von Zellen.
DE68907933T2 (de) Therapeutisches Mittel für Thrombocytopenia.
DE69518448D1 (de) Hydroxyfunktionalisierte Pyrrolizidinkatalysator-Zusammensetzungen für die Herstellung von Polyurethanen
DE29721247U1 (de) Injektionssystem für die kombinierte Kontrastmittel-Kochsalzlösung-Bolusinjektion
DE69012462T2 (de) Spekulum für einmaligen Gebrauch.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition